Research programme: inflammasome inhibitors - Selvita

Drug Profile

Research programme: inflammasome inhibitors - Selvita

Alternative Names: SEL212

Latest Information Update: 13 Aug 2016

Price : $50

At a glance

  • Originator Selvita
  • Class
  • Mechanism of Action Inflammasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders; Inflammation

Most Recent Events

  • 28 Jul 2016 Early research in Autoimmune disorders in Scotland (unspecified route)
  • 28 Jul 2016 Early research in Inflammation in Scotland (unspecified route)
  • 28 Jul 2016 Selvita and Nodthera agree to co-develop inflammasome inhibitors for Autoimmune disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top